SLP Stock Cash Flow Statements

Simulations Plus Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Simulations Plus Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-05-31	2025-02-28	2024-11-30	2024-08-31	2024-05-31	2024-02-29	2023-11-30	2023-08-31	2023-05-31	2023-02-28	2022-11-30	2022-08-31	2022-05-31	2022-02-28	2021-11-30	2021-08-31	2021-05-31	2021-02-28	2020-11-30	2009-08-31

cash flows from operating activities
net income	-67,317,000	3,074,000	206,000	843,000	3,137,000	4,029,000	1,945,000	534,000	4,008,000	4,174,000	1,245,000	961,000	4,087,000	4,409,000	3,026,000	305,000	3,787,000	3,211,000	2,479,000	163,156
adjustments to reconcile net income to net cash from operating activities
depreciation and amortization	2,318,000	2,274,000	2,265,000	2,206,000	1,263,000	1,105,000	1,091,000	1,037,000	945,000	935,000	923,000	850,000	884,000	995,000	845,000	928,000	886,000	911,000	865,000
change in fair value of contingent consideration	0			-1,369,000	-600,000	440,000	-110,000
discharge of holdback obligation related to immunetrics acquisition	0
amortization of investment discounts	-4,000	-21,000	-39,000	-31,000
stock-based compensation	1,414,000	1,692,000	1,724,000	1,596,000	1,795,000	1,785,000	1,362,000	1,280,000	1,248,000	1,264,000	1,036,000	758,000	766,000	791,000	722,000	709,000	705,000	804,000	532,000	53,634
deferred income taxes	-7,174,000	-947,000	40,000	-399,000	-481,000	-497,000	-388,000	-749,000	-1,749,000			-224,000	-470,000	37,000	387,000	-544,000	-90,000	-41,000	47,000	-32,472
income from disposal of assets
impairments
currency translation adjustments	40,000	-26,000	-42,000	20,000	-56,000	-15,000	-54,000	-7,000	144,000	-22,000	52,000	-14,000	24,000	-38,000	-237,000	-137,000	40,000
increase in
accounts receivable	1,713,000	-3,689,000	-3,668,000	3,072,000	2,970,000	-2,768,000	-145,000	524,000	1,184,000	301,000	2,088,000	4,800,000	-3,548,000	-3,216,000	-1,972,000	3,111,000	-1,656,000	-3,975,000	91,000	680,861
prepaid income taxes	421,000	952,000	-130,000	-995,000	162,000	-1,327,000	767,000	-804,000	397,000	595,000	399,000	-1,069,000	127,000	135,000	428,000	-520,000	758,000	-690,000	410,000
prepaid expenses and other assets	-102,000	-332,000	708,000	-645,000	-328,000	345,000	-1,515,000	929,000	-363,000	199,000	-1,266,000	-127,000	-66,000	1,253,000	21,000	-94,000	-194,000	329,000	-141,000
accounts payable	457,000	86,000	518,000	-991,000	298,000	43,000	173,000	-213,000	7,000	112,000	13,000	-194,000	10,000	390,000	-368,000	90,000	-102,000	66,000	-15,000	-66,362
other liabilities	-1,864,000	3,359,000	-4,095,000	-746,000	-1,167,000	3,274,000	-2,129,000	671,000	1,171,000	-1,117,000	107,000
deferred revenue	998,000	115,000	1,235,000	-897,000	-1,020,000	-203,000	-440,000	-132,000	1,122,000	-1,014,000	200,000	781,000	842,000	556,000	34,000	-8,000	19,000	279,000	-56,000	39,857
net cash from operating activities	8,144,000	5,669,000	-1,274,000	1,664,000	5,684,000	5,810,000	162,000	3,060,000	8,548,000	5,541,000	4,707,000	7,927,000	3,794,000	2,597,000	3,582,000	8,273,000	4,296,000	1,301,000	5,333,000	875,929
capex	-297,000	-66,000	-86,000	-16,000	-117,000	0	0	-196,000	59,000	-207,000	-109,000	-79,000	-30,000	-149,000	-561,000	-661,000	-383,000	-378,000	-205,000	-9,783
free cash flows	7,847,000	5,603,000	-1,360,000	1,648,000	5,567,000	5,810,000	162,000	2,864,000	8,607,000	5,334,000	4,598,000	7,848,000	3,764,000	2,448,000	3,021,000	7,612,000	3,913,000	923,000	5,128,000	866,146
cash flows from investing activities
purchases of property and equipment	-297,000	-66,000	-86,000	-16,000	-117,000			-196,000	59,000	-207,000	-109,000	-79,000	-30,000	-149,000	-561,000	-661,000	-383,000	-378,000	-205,000	-9,783
purchase of short-term investments	-1,500,000	-1,500,000	-3,500,000	0	-18,170,000	-18,445,000	-30,544,000	-23,210,000	-24,679,000	-17,638,000	-29,518,000
proceeds from maturities of short-term investments	10,397,000	2,120,000	1,500,000	-4,000	34,841,000	21,474,000	14,778,000	32,900,000	33,856,000	24,013,000	24,138,000
proceeds from sales of investments	0			0
purchase of long-term investments
purchased intangibles	-26,000	-156,000	-186,000	-33,000	-41,000	-220,000	-247,000	-82,000	-442,000	-38,000	-39,000
net working capital & excess cash settlement - pro-ficiency acquisition	0	0	-227,000
capitalized computer software development costs	-767,000	-709,000	-639,000	-674,000	-801,000	-868,000	-851,000	-669,000	-875,000	-781,000	-894,000	-885,000	-759,000	-669,000	-838,000	-676,000	-799,000	-746,000	-728,000	-183,225
net cash from investing activities	7,807,000	684,000	-3,138,000	-99,500,000	69,913,000	-7,516,000	-16,864,000	520,000	7,919,000	5,349,000	-6,422,000	2,303,000	-17,087,000	17,138,000	1,951,000	-27,607,000	12,761,000	13,978,000	-25,874,000	-193,008
cash flows from financing activities
payment of dividends				-1,202,000	-1,200,000	-1,198,000	-1,196,000	-1,196,000	-1,200,000	-1,195,000	-1,218,000	-1,214,000	-1,212,000	-1,211,000	-1,209,000	-1,208,000	-1,207,000	-1,201,000	-1,195,000
payments on contracts payable	0			0								0
proceeds from the exercise of stock options	7,000	28,000	288,000	257,000	164,000	146,000	164,000	8,000	572,000	205,000	758,000	198,000	152,000	169,000	372,000	49,000	576,000	656,000	180,000	34,554
net cash from financing activities	7,000	-1,548,000	288,000	-945,000	-3,536,000	-1,052,000	-1,032,000	-1,188,000	-628,000	-20,990,000	-460,000	-1,016,000	-4,727,000	-1,042,000	-837,000	-2,493,000	-631,000	-545,000	-1,015,000	-582,050
net increase in cash and cash equivalents	15,958,000			-98,781,000				2,392,000	15,839,000	-10,100,000	-2,175,000	9,214,000	-18,020,000	18,693,000	4,696,000	-21,827,000	16,426,000	14,734,000	-21,556,000	100,871
cash and cash equivalents, beginning of period	0	0	10,311,000	0	0
cash and cash equivalents, end of period	15,958,000	4,805,000	6,187,000	-98,781,000	72,061,000	-2,758,000	39,789,000	2,392,000	15,839,000	-10,100,000	49,392,000	9,214,000	-18,020,000	18,693,000	41,680,000	-21,827,000	16,426,000	14,734,000	27,651,000	100,871
supplemental disclosures of cash flow information
income taxes paid	404,000	504,000	112,000	1,475,000	1,072,000	3,046,000	96,000	1,645,000	1,466,000			1,232,000	1,080,000	898,000	23,000	964,000	15,000	821,000	57,000	171,906
supplemental disclosures of non-cash activities
measurement period adjustments
non-cash investing and financing activities
right of use assets capitalized		0	451,000									0	0
unrealized gains on available-for-sale securities			4,000
net decrease in cash and cash equivalents			-4,124,000			-2,758,000	-17,734,000
impairment of other intangibles
accrued income taxes								-800,000
business acquisition, net of cash acquired
repurchase and retirement of common shares								0	0
stock issued for acquisition of lixoft
creation of contract liabilities from acquisition of subsidiaries
amortization of investment (discounts) premiums						-401,000	-395,000	-396,000	-359,000	-289,000	-90,000
cash and cash equivalents, beginning of year							57,523,000	0	0	0	51,567,000	0	0	0	36,984,000	0	0	0	49,207,000	0
gain from disposal of assets
acquisition of immunetrics, net of cash acquired
change in value of contingent consideration												0	40,000	122,000	121,000	122,000	121,000	122,000	121,000
amortization of investment premiums												185,000	371,000	512,000	610,000	598,000
proceeds from sale of short-term investments												33,189,000	29,122,000	30,743,000	16,067,000	32,161,000	37,118,000	24,932,000	6,018,000
cash used to acquire subsidiaries
cash received in acquisition
proceeds from follow-on public offering
creation of contract liabilities for acquisition of subsidiaries
accrued payroll and other incomes													727,000	-1,747,000	-1,637,000	3,006,000	-293,000	591,000	49,000	26,578
purchases of short-term investments													-45,420,000	-12,787,000	-12,717,000		-23,175,000	-9,830,000	-30,959,000
cash flows used in financing activities
revenue in excess of billings															1,667,000
billings in excess of revenue															-65,000
revenues in excess of billings																733,000	-46,000	-1,000,000	256,000
billings in excess of revenues																-10,000	-131,000	52,000	65,000
purchases of intellectual property
right-of-use assets capitalized
amortization of note premiums																		646,000	630,000
cash flows used in investing activities
right of use assets acquired
stock issued for acquisition of cognigen corporation
depreciation and amortization of property and equipment																				5,284
amortization of capitalized computer software development costs																				138,025
amortization of intellectual property
shares issued to directors for services
accrued bonus
amortization of customer relationships																				4,364
(income)/income from discontinued operations
excess tax benefits from share-based arrangement
(gain)/income from sale of assets
accounts receivable and contracts receivable
income tax refundable
inventory																				49,464
net cash from operating activities of continuing operations
net cash from operating activities of discontinued operations
proceeds from sale of words+, inc.
proceeds from sale of assets
purchase of royalty
net cash from investing activities of continuing operations
net cash from investing activities of discontinued operations
repurchase of common stock																				-616,604
net cash from financing activities of continuing operations
net increase in cash and cash equivalents from continuing operations
net increase in cash and cash equivalents from discontinued operations
interest paid
net cash (used in) financing activities of continuing operations
net (decrease) in cash and cash equivalents from discontinued operations
bad debts																				0
gain on sales of property and equipment
accrued warranty and service costs																				3,037
proceeds from sale of property and equipment
gain on sale of equipment
excess tax benefits from share-based arrangements
proceeds from sale of investments																				0
other assets																				-73,808
accrued bonuses to officers
investment in securities
adjustments to reconcile net income to net cash
provided by operating activities

We provide you with 20 years of cash flow statements for Simulations Plus stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Simulations Plus stock. Explore the full financial landscape of Simulations Plus stock with our expertly curated income statements.

The information provided in this report about Simulations Plus stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.